These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma. Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238 [TBL] [Abstract][Full Text] [Related]
4. Is it good or bad to find a BRAF mutation? Flaherty KT J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552 [No Abstract] [Full Text] [Related]
5. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report. Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157 [TBL] [Abstract][Full Text] [Related]
6. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib. Vergote V; Dierickx D; Janssens A; Verhoef G; Tousseyn T; Vandenberghe P; Wolter P; Delforge M Ann Hematol; 2014 Dec; 93(12):2087-9. PubMed ID: 24863690 [No Abstract] [Full Text] [Related]
7. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367 [TBL] [Abstract][Full Text] [Related]
8. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Menzies AM; Long GV Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796 [TBL] [Abstract][Full Text] [Related]
9. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559 [TBL] [Abstract][Full Text] [Related]
10. Multiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma. Carrera C; Puig-Butillè JA; Tell-Marti G; García A; Badenas C; Alós L; Puig S; Malvehy J JAMA Dermatol; 2015 May; 151(5):544-8. PubMed ID: 25651238 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930 [TBL] [Abstract][Full Text] [Related]
12. The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations. Ponti G; Pellacani G; Tomasi A; Gelsomino F; Spallanzani A; Depenni R; Al Jalbout S; Simi L; Garagnani L; Borsari S; Conti A; Ruini C; Fontana A; Luppi G J Clin Pathol; 2013 May; 66(5):441-5. PubMed ID: 23463675 [TBL] [Abstract][Full Text] [Related]
14. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704 [TBL] [Abstract][Full Text] [Related]
15. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Gibney GT; Zager JS Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583 [TBL] [Abstract][Full Text] [Related]
16. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966 [TBL] [Abstract][Full Text] [Related]
17. Potassium iodide in successful treatment of erythema nodosum-like lesions induced by combination therapy with dabrafenib and trametinib. Sawada H; Kanehisa F; Katoh N; Asai J J Dermatol; 2020 Jan; 47(1):e7-e8. PubMed ID: 31587335 [No Abstract] [Full Text] [Related]
18. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib. Blachly JS; Lozanski G; Lucas DM; Grever MR; Kendra K; Andritsos LA J Natl Compr Canc Netw; 2015 Jan; 13(1):9-13; quiz 13. PubMed ID: 25583765 [TBL] [Abstract][Full Text] [Related]